Theraclion SA (TCLIF)
OTCMKTS · Delayed Price · Currency is USD
0.3200
+0.3198 (159,900.00%)
At close: Aug 26, 2024
Theraclion Revenue
In the year 2024, Theraclion had annual revenue of 830.21K EUR, down -54.44%. Theraclion had revenue of 1.07M in the half year ending December 31, 2024, with 20.21% growth.
Revenue
830.21K EUR
Revenue Growth
-54.44%
P/S Ratio
42.41
Revenue / Employee
25.94K EUR
Employees
32
Market Cap
36.45M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 830.21K | -992.01K | -54.44% |
| Dec 31, 2023 | 1.82M | 586.77K | 47.49% |
| Dec 31, 2022 | 1.24M | -245.50K | -16.58% |
| Dec 31, 2021 | 1.48M | 736.95K | 99.05% |
| Dec 31, 2020 | 744.00K | -2.39M | -76.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 221.55M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 2.61M |